The National Institute of Neurological Disorders and Stroke (NINDS) is supporting a randomized, multicenter phase III clinical trial comparing combination therapy with interferon β? la (Avonex) and glatiramer acetate (Copaxone) to either agent alone in the treatment of the relapsing-remitting (RR) form of multiple sclerosis (MS).

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2010
Total Cost
$780,184
Indirect Cost
City
State
Country
Zip Code